Pavlyha Marianna, Hunter Madeleine, Nowygrod Roman, Patel Virenda, Morrissey Nicholas, Bajakian Danielle, Li Yihao, Reyes-Soffer Gissette
Department of Medicine, Division of Preventive Medicine and Nutrition, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
Department of Surgery, Division of Vascular Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
JVS Vasc Sci. 2024 Jun 11;5:100211. doi: 10.1016/j.jvssci.2024.100211. eCollection 2024.
High lipoprotein (a) [Lp(a)] is associated with adverse limb events in patients undergoing lower extremity revascularization. Lp(a) levels are genetically pre-determined, with gene encoding for two apolipoprotein (a) [apo(a)] isoforms. Isoform size variations are driven by the number of kringle IV type 2 (KIV-2) repeats. Lp(a) levels are inversely correlated with isoform size. In this study, we examined the role of Lp(a) levels, apo(a) size, and inflammatory markers with lower extremity revascularization outcomes.
Twenty-five subjects with chronic peripheral arterial disease (PAD) underwent open or endovascular lower extremity revascularization (mean age, 66.7 ± 9.7 years; Female = 12; Male = 13; Black = 8; Hispanic = 5; and White = 12). Pre- and postoperative medical history, self-reported symptoms, ankle-brachial indices (ABIs), and lower extremity duplex ultrasounds were obtained. Plasma Lp(a), apoB100, lipid panel, and pro-inflammatory markers (IL-6, IL-18, hs-CRP, TNFα) were assayed preoperatively. Isoform size was estimated using gel electrophoresis and weighted isoform size () calculated based on % isoform expression. Firth logistic regression was used to examine the relationship between Lp(a) levels and with procedural outcomes: symptoms (better/worse), early primary patency at 2 to 4 weeks, ABIs, and reintervention within 3 to 6 months. We controlled for age, sex, history of diabetes, smoking, statin, antiplatelet, and anticoagulation use.
Median plasma Lp(a) level was 108 (interrquartile range, 44-301) nmol/L. The mean apoB100 level was 168.0 ± 65.8 mg/dL. These values were not statistically different among races. We found no association between Lp(a) levels and w with measured plasma pro-inflammatory markers. However, smaller apo(a) was associated with occlusion of the treated lesion(s) in the postoperative period (odds ratio, 1.97; 95% confidence interval, 1.01-3.86; < .05). The relationship of smaller apo(a) with reintervention was not as strong (odds ratio, 1.57; 95% confidence interval, 0.96-2.56; = .07). We observed no association between with patient reported symptoms or change in ABIs.
In this small study, subjects with smaller apo(a) isoform size undergoing peripheral arterial revascularization were more likely to experience occlusion in the postoperative period and/or require reintervention. Larger cohort studies identifying the mechanism and validating these preliminary data are needed to improve understanding of long-term peripheral vascular outcomes.
高脂蛋白(a)[Lp(a)]与接受下肢血管重建术的患者发生不良肢体事件有关。Lp(a)水平由基因预先决定,该基因编码两种载脂蛋白(a)[apo(a)]异构体。异构体大小的变化由kringle IV型2(KIV-2)重复序列的数量驱动。Lp(a)水平与异构体大小呈负相关。在本研究中,我们研究了Lp(a)水平、apo(a)大小和炎症标志物对下肢血管重建术结果的作用。
25例慢性外周动脉疾病(PAD)患者接受了开放性或血管腔内下肢血管重建术(平均年龄66.7±9.7岁;女性12例;男性13例;黑人8例;西班牙裔5例;白人12例)。获取术前和术后的病史、自我报告的症状、踝臂指数(ABI)和下肢双功超声检查结果。术前检测血浆Lp(a)、apoB100、血脂谱和促炎标志物(IL-6、IL-18、hs-CRP、TNFα)。使用凝胶电泳估计异构体大小,并根据异构体表达百分比计算加权异构体大小()。采用Firth逻辑回归分析Lp(a)水平和与手术结果之间的关系:症状(改善/恶化)、2至4周时的早期原发性通畅率、ABI以及3至6个月内的再次干预。我们对年龄、性别、糖尿病史、吸烟、他汀类药物、抗血小板药物和抗凝药物的使用进行了控制。
血浆Lp(a)水平中位数为108(四分位间距,44 - 301)nmol/L。apoB100平均水平为168.0±6mg/dL。这些值在不同种族之间无统计学差异。我们发现Lp(a)水平和与测得的血浆促炎标志物之间无关联。然而,较小的apo(a)与术后治疗病变的闭塞有关(比值比,1.97;95%置信区间,1.01 - 3.86;P <.05)。较小的apo(a)与再次干预的关系不那么强(比值比,1.57;95%置信区间,0.96 - 2.56;P =.07)。我们未观察到与患者报告的症状或ABI变化之间的关联。
在这项小型研究中,接受外周动脉血管重建术且apo(a)异构体较小的受试者在术后更有可能发生闭塞和/或需要再次干预。需要更大规模的队列研究来确定机制并验证这些初步数据,以增进对长期外周血管结局的理解。